Literature DB >> 12460460

Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma.

Hitoshi Takayama1, Tetsuya Takakuwa, Yuichi Tsujimoto, Norio Nonomura, Akihiko Okuyama, Katsuyuki Aozasa.   

Abstract

Renal cell carcinoma (RCC) expresses Fas antigen on the cell surface, and thus could be sensitive to apoptosis induced by the binding of Fas ligand. Fas gene mutations might be involved in the development of RCC. Fas gene mutations were examined in genomic DNA extracted from RCC lesions. With use of laser capture methods, one RCC and one non-neoplastic lesion per case were microdissected from 15 patients with RCC. Polymerase chain reaction-amplified products were directly sequenced. Loss of heterozygosity (LOH) was examined at four sites of known polymorphism. Mutations of the Fas gene were detected in 3 RCC lesions from 3 (20%) of 15 cases. All mutations were point mutations, 2 missense and one silent, in exons 7 and 9. Non-neoplastic tissues never showed Fas gene mutations. Nine of 15 cases (60.0%) were heterozygous for one or more sites of the known biallelic polymorphisms, i.e., at nucleotides -1377, -670, 416, and 836. Two of these 9 cases showed LOH at promoter region -670. Mouse T-cell lymphoma cells transfected with missense mutated genes were resistant to apoptosis induced by anti-Fas antibody, indicating these to be loss-of-function mutations. The results of the present study suggest that Fas gene mutations play a role in the pathogenesis of RCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460460      PMCID: PMC5926898          DOI: 10.1111/j.1349-7006.2002.tb01224.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  20 in total

1.  Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.

Authors:  K Grønbaek; P T Straten; E Ralfkiaer; V Ahrenkiel; M K Andersen; N E Hansen; J Zeuthen; K Hou-Jensen; P Guldberg
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

Review 2.  Apoptosis by death factor.

Authors:  S Nagata
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

3.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.

Authors:  M Thome; P Schneider; K Hofmann; H Fickenscher; E Meinl; F Neipel; C Mattmann; K Burns; J L Bodmer; M Schröter; C Scaffidi; P H Krammer; M E Peter; J Tschopp
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

4.  Frequent mutations of Fas gene in thyroid lymphoma.

Authors:  T Takakuwa; Z Dong; H Takayama; F Matsuzuka; S Nagata; K Aozasa
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

5.  Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.

Authors:  S H Lee; M S Shin; W S Park; S Y Kim; S M Dong; J H Pi; H K Lee; H S Kim; J J Jang; C S Kim; S H Kim; J Y Lee; N J Yoo
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

6.  Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.

Authors:  S H Lee; M S Shin; W S Park; S Y Kim; H S Kim; J Y Han; G S Park; S M Dong; J H Pi; C S Kim; S H Kim; J Y Lee; N J Yoo
Journal:  Oncogene       Date:  1999-06-24       Impact factor: 9.867

7.  Mutations in the Fas antigen in patients with multiple myeloma.

Authors:  T H Landowski; N Qu; I Buyuksal; J S Painter; W S Dalton
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

8.  A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen.

Authors:  N Itoh; S Nagata
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

9.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

10.  Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.

Authors:  U Ramp; M Dejosez; C Mahotka; B Czarnotta; T Kalinski; M Wenzel; I Lorenz; M Müller; P Krammer; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  2 in total

1.  Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.

Authors:  Gudrun Knechtel; Günter Hofmann; Armin Gerger; Wilfried Renner; Tanja Langsenlehner; Joanna Szkandera; Gerald Wolf; Hellmut Samonigg; Peter Krippl; Uwe Langsenlehner
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-05       Impact factor: 4.553

2.  Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma.

Authors:  R Maruyama; K Yamana; T Itoi; N Hara; V Bilim; T Nishiyama; K Takahashi; Y Tomita
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.